Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. [electronic resource]
Producer: 20010614Description: 4258-65 p. digitalISSN:- 0008-5472
- Amino Acid Sequence
- Azacitidine -- analogs & derivatives
- Base Sequence
- Chromosome Mapping
- Cisplatin -- pharmacology
- Cloning, Molecular
- DNA, Neoplasm -- genetics
- Decitabine
- Down-Regulation
- Drug Resistance, Multiple -- genetics
- Drug Resistance, Neoplasm
- Female
- Gene Expression Regulation, Neoplastic
- Gene Silencing
- HSP40 Heat-Shock Proteins
- Heat-Shock Proteins -- biosynthesis
- Humans
- In Situ Hybridization, Fluorescence
- Loss of Heterozygosity
- Molecular Sequence Data
- Ovarian Neoplasms -- drug therapy
- Oximes
- Paclitaxel -- pharmacology
- Piperazines
- Reverse Transcriptase Polymerase Chain Reaction
- Sequence Homology, Amino Acid
- Topotecan -- pharmacology
- Transfection
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.